메뉴 건너뛰기




Volumn 103, Issue 1, 2010, Pages 58-65

The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: A review of the evidence

Author keywords

Insulin; Oral medications; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIPHASIC INSULIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SHORT ACTING DRUG; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

EID: 75149116215     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181c35776     Document Type: Review
Times cited : (15)

References (78)
  • 1
    • 59149103879 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithim for the initiation and adjustment of therapy
    • Nathan D, Buse J, Davidson B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithim for the initiation and adjustment of therapy. Diabetes Care 2008;31:1-11
    • (2008) Diabetes Care , vol.31 , pp. 1-11
    • Nathan, D.1    Buse, J.2    Davidson, B.3
  • 2
    • 0027935577 scopus 로고    scopus 로고
    • Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double- blind controlled study
    • Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double- blind controlled study. Diabetes Care 1999;17:1100-1109
    • (1999) Diabetes Care , vol.17 , pp. 1100-1109
    • Hermann, L.S.1    Schersten, B.2    Bitzen, P.O.3
  • 3
    • 0029099086 scopus 로고
    • Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
    • The Multicenter Metformin Study Group
    • Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-549
    • (1995) N Engl J Med , vol.333 , pp. 541-549
    • Defronzo, R.A.1    Goodman, A.M.2
  • 4
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS-34)
    • UK Prospective Diabetes Study (UKPDS) Group
    • Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS-34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865
    • (1998) Lancet , vol.352 , pp. 854-865
  • 5
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • Holman R, Sanjoy P, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1-13
    • (2008) N Engl J Med , vol.359 , pp. 1-13
    • Holman, R.1    Sanjoy, P.2    Bethel, M.A.3
  • 6
  • 7
    • 0345425783 scopus 로고    scopus 로고
    • Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: A randomized, double blind, placebo-controlled trial
    • Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double blind, placebo-controlled trial. Ann Intern Med 1999;131:182-188
    • (1999) Ann Intern Med , vol.131 , pp. 182-188
    • Santa, L.1    Sinding, J.2    Raskin, P.3
  • 8
    • 0031767174 scopus 로고    scopus 로고
    • The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control
    • Robinson A, Burke J, Robinson S, et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21:701-705
    • (1998) Diabetes Care , vol.21 , pp. 701-705
    • Robinson, A.1    Burke, J.2    Robinson, S.3
  • 9
    • 0031793008 scopus 로고    scopus 로고
    • Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: An open-label randomized trial
    • Relimpio F, Pumar A, Losada F, et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial. Diabetes Med 1998;12:997-1002
    • (1998) Diabetes Med , vol.12 , pp. 997-1002
    • Relimpio, F.1    Pumar, A.2    Losada, F.3
  • 10
    • 0034154095 scopus 로고    scopus 로고
    • Intensive insulin therapy combined with metformin in obese type 2 diabetic patients
    • Fristche A, Schmullin RM, Haring HU, et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000;37:13-18
    • (2000) Acta Diabetol , vol.37 , pp. 13-18
    • Fristche, A.1    Schmullin, R.M.2    Haring, H.U.3
  • 11
    • 0033946189 scopus 로고    scopus 로고
    • Combined metformin and insulin therapy for patients with type 2 diabetes mellitus
    • Ponssen H, Elte J, Lehert P, et al. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 2000;22: 709-718
    • (2000) Clin Ther , vol.22 , pp. 709-718
    • Ponssen, H.1    Elte, J.2    Lehert, P.3
  • 12
    • 0036782581 scopus 로고    scopus 로고
    • Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes
    • Strowig S, Aviles-Santa M, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691-1698
    • (2002) Diabetes Care , vol.25 , pp. 1691-1698
    • Strowig, S.1    Aviles-Santa, M.2    Raskin, P.3
  • 13
    • 0242269000 scopus 로고    scopus 로고
    • The Treat to Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    • Insulin Glargine 4002 Study Investigators
    • Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat to Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
    • (2003) Diabetes Care , vol.26 , pp. 3080-3086
    • Riddle, M.C.1    Rosenstock, J.2    Gerich, J.3
  • 14
    • 33244479164 scopus 로고    scopus 로고
    • Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
    • Yki-Järvinen H, Tiikkainen M, Vahatalo M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451
    • (2006) Diabetologia , vol.49 , pp. 442-451
    • Yki-Järvinen, H.1    Tiikkainen, M.2    Vahatalo, M.3
  • 15
    • 17844366606 scopus 로고    scopus 로고
    • Continuing metformin when starting insulin in patients with type 2 diabetes: A double-blind randomized placebo-controlled trial
    • Douek IF, Allen SE, Ewings P, et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22:634-640
    • (2005) Diabet Med , vol.22 , pp. 634-640
    • Douek, I.F.1    Allen, S.E.2    Ewings, P.3
  • 16
    • 38749103090 scopus 로고    scopus 로고
    • Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes
    • Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab Res Rev 2008;24:3-13
    • (2008) Diabetes Metab Res Rev , vol.24 , pp. 3-13
    • Raskin, P.1
  • 17
    • 75149171350 scopus 로고    scopus 로고
    • Metformin. Available at, Accessed March 30, 2009
    • Metformin. Available at: www.drugstore.com. Accessed March 30, 2009
  • 18
    • 0005169502 scopus 로고    scopus 로고
    • United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
    • United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study Group
    • United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998;128:165-175
    • (1998) Ann Intern Med , vol.128 , pp. 165-175
  • 19
    • 0032483719 scopus 로고    scopus 로고
    • Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial
    • Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998;280:1490-1496
    • (1998) JAMA , vol.280 , pp. 1490-1496
    • Testa, M.A.1    Simonson, D.C.2
  • 20
    • 54549107987 scopus 로고    scopus 로고
    • Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: A randomized trial
    • Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-539
    • (2008) Ann Intern Med , vol.149 , pp. 531-539
    • Esposito, K.1    Ciotola, M.2    Maiorino, M.I.3
  • 21
    • 33846580098 scopus 로고    scopus 로고
    • Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus
    • Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007; 55:182-188
    • (2007) J Am Geriatr Soc , vol.55 , pp. 182-188
    • Janka, H.U.1    Plewe, G.2    Busch, K.3
  • 22
    • 0036483958 scopus 로고    scopus 로고
    • Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)
    • U.K. Prospective Diabetes Study Group
    • Wright A, Burden AC, Paisey RB, et al.; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336
    • (2002) Diabetes Care , vol.25 , pp. 330-336
    • Wright, A.1    Burden, A.C.2    Paisey, R.B.3
  • 23
    • 12844250551 scopus 로고    scopus 로고
    • Good glycemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride
    • HOE901/4009 Study Group
    • Standl E, Maxeiner S, Raptis S, et al.; HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28:419-420
    • (2005) Diabetes Care , vol.28 , pp. 419-420
    • Standl, E.1    Maxeiner, S.2    Raptis, S.3
  • 24
    • 12844276465 scopus 로고    scopus 로고
    • Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
    • Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-259
    • (2005) Diabetes Care , vol.28 , pp. 254-259
    • Janka, H.U.1    Plewe, G.2    Riddle, M.C.3
  • 25
    • 35548947584 scopus 로고    scopus 로고
    • Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    • Holman R, Thorne K, Farmer A, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357: 1716-1730
    • (2007) N Engl J Med , vol.357 , pp. 1716-1730
    • Holman, R.1    Thorne, K.2    Farmer, A.3
  • 26
    • 0030758711 scopus 로고    scopus 로고
    • Rates of hypoglycemia in users of sulfonylureas
    • Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-741
    • (1997) J Clin Epidemiol , vol.50 , pp. 735-741
    • Van Staa, T.1    Abenhaim, L.2    Monette, J.3
  • 27
    • 0038131919 scopus 로고    scopus 로고
    • Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial
    • 4001 Study Group
    • Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-959
    • (2003) Ann Intern Med , vol.138 , pp. 952-959
    • Fritsche, A.1    Schweitzer, M.A.2    Häring, H.U.3
  • 28
    • 33845537033 scopus 로고    scopus 로고
    • Weight changes following the initiation of new anti-hyperglycaemic therapies
    • Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007; 9:96-102
    • (2007) Diabetes Obes Metab , vol.9 , pp. 96-102
    • Nichols, G.A.1    Gomez-Caminero, A.2
  • 29
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853
    • (1998) Lancet , vol.352 , pp. 837-853
  • 30
    • 0027935577 scopus 로고    scopus 로고
    • Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double- blind controlled study
    • Hermann LS, Scherstén B, Bitzén PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double- blind controlled study. Diabetes Care 1994;17:1100-1109
    • (1994) Diabetes Care , vol.17 , pp. 1100-1109
    • Hermann, L.S.1    Scherstén, B.2    Bitzén, P.O.3
  • 31
    • 33846690465 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin
    • Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-394
    • (2007) Diabetes Care , vol.30 , pp. 389-394
    • Gangji, A.S.1    Cukierman, T.2    Gerstein, H.C.3
  • 32
    • 75149197288 scopus 로고    scopus 로고
    • Glyburide. Available at: Accessed March 30, 2009
    • Glyburide. Available at: www.drugstore.com. Accessed March 30, 2009
  • 33
    • 0032005178 scopus 로고    scopus 로고
    • Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double blind, placebo-controlled trial
    • Maggs Dg, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double blind, placebo-controlled trial. Ann Intern Med 1998;128:176-185
    • (1998) Ann Intern Med , vol.128 , pp. 176-185
    • Dg, M.1    Buchanan, T.A.2    Burant, C.F.3
  • 34
    • 0034923501 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma and metabolic disease
    • Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70:341-367
    • (2001) Annu Rev Biochem , vol.70 , pp. 341-367
    • Willson, T.M.1    Lambert, M.H.2    Kliewer, S.A.3
  • 35
    • 0035992811 scopus 로고    scopus 로고
    • Glitazones: Clinical effects and molecular mechanisms
    • Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217-224
    • (2002) Ann Med , vol.34 , pp. 217-224
    • Stumvoll, M.1    Haring, H.U.2
  • 36
    • 0033754530 scopus 로고    scopus 로고
    • Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
    • The Pioglitazone 001 Study Group
    • Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-1611
    • (2000) Diabetes Care , vol.23 , pp. 1605-1611
    • Aronoff, S.1    Rosenblatt, S.2    Braithwaite, S.3
  • 37
    • 0033123466 scopus 로고    scopus 로고
    • Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelveweek, randomized, placebo-controlled study
    • Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelveweek, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1:165-172
    • (1999) Diabetes Obes Metab , vol.1 , pp. 165-172
    • Patel, J.1    Anderson, R.J.2    Rappaport, E.B.3
  • 38
    • 0034933056 scopus 로고    scopus 로고
    • Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
    • Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:71-72
    • (2001) Am J Med , vol.111 , pp. 71-72
    • Kipnes, M.S.1    Krosnick, A.2    Rendell, M.S.3
  • 39
    • 0033975057 scopus 로고    scopus 로고
    • Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients
    • Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2007;17:40-47
    • (2007) Diabet Med , vol.17 , pp. 40-47
    • Wolffenbuttel, B.H.1    Gomis, R.2    Squatrito, S.3
  • 40
    • 33645988220 scopus 로고    scopus 로고
    • Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (-60 years): The Rosiglitazone Early vs. SULfonylureaTitration (RESULT) Study
    • RESULT Study Group
    • Rosenstock J, Goldstein BJ, Vinik AI, et al.; RESULT Study Group. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (-60 years): the Rosiglitazone Early vs. SULfonylureaTitration (RESULT) Study. Diabetes Obes Metab 2006;8:49-57
    • (2006) Diabetes Obes Metab , vol.8 , pp. 49-57
    • Rosenstock, J.1    Goldstein, B.J.2    Vinik, A.I.3
  • 41
    • 0034531195 scopus 로고    scopus 로고
    • Pioglitazone hydrochloride in combination with metformin in the treatment of type2 diabetes mellitus: A randomized, placebo-controlled study
    • The Pioglitazone 027 Study Group
    • Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-1409
    • (2000) Clin Ther , vol.22 , pp. 1395-1409
    • Einhorn, D.1    Rendell, M.2    Rosenzweig, J.3
  • 42
    • 33644848645 scopus 로고    scopus 로고
    • Rosiglitazone plus metformin is effective and well tolerated in clinical practice: Results from large observational studies in people with type 2 diabetes
    • Rosak C, Petzoldt R, Wolf R, et al. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract 2005;59:1131-1136
    • (2005) Int J Clin Pract , vol.59 , pp. 1131-1136
    • Rosak, C.1    Petzoldt, R.2    Wolf, R.3
  • 43
    • 0036284873 scopus 로고    scopus 로고
    • Pioglitazone 014 Study. Efficacy and safety of pioglitazone in type 2 diabetes: A randomized, placebo-controlled study in patients receiving stable insulin therapy
    • Rosenstock J, Einhorn D, Hershon K, et al.; Pioglitazone 014 Study. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-257
    • (2002) Int J Clin Pract , vol.56 , pp. 251-257
    • Rosenstock, J.1    Einhorn, D.2    Hershon, K.3
  • 44
    • 20644453108 scopus 로고    scopus 로고
    • Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month randomized multicenter parallel group study
    • H6E-MC-GLAT study group
    • Mattoo V, Eckland D, Widel M, et al.; H6E-MC-GLAT study group. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, multicenter, parallel group study. Clin Ther 2005;27:554-567
    • (2005) Clin Ther , vol.27 , pp. 554-567
    • Mattoo, V.1    Eckland, D.2    Widel, M.3
  • 45
    • 33645996039 scopus 로고    scopus 로고
    • Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: Results of a double-blind, multicentre, randomized study
    • Pioglitazone 343 Study Group
    • Davidson JA, Perez A, Zhang J; Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006;8:164-174
    • (2006) Diabetes Obes Metab , vol.8 , pp. 164-174
    • Davidson, J.A.1    Perez, A.2    Zhang, J.3
  • 46
    • 38149060084 scopus 로고    scopus 로고
    • Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improve vascular dysfunction by different mechanisms
    • Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improve vascular dysfunction by different mechanisms. Diabetes Care 2008;31: 121-127
    • (2008) Diabetes Care , vol.31 , pp. 121-127
    • Fernandez, M.1    Triplitt, C.2    Wajcberg, E.3
  • 47
    • 34347396392 scopus 로고    scopus 로고
    • Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy
    • Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007;9:512-520
    • (2007) Diabetes Obes Metab , vol.9 , pp. 512-520
    • Berhanu, P.1    Perez, A.2    Yu, S.3
  • 48
    • 0035408779 scopus 로고    scopus 로고
    • A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    • Rosiglitazone Clinical Trials Study Group
    • Raskin P, Rendell M, Riddle MC, et al.; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-1232
    • (2001) Diabetes Care , vol.24 , pp. 1226-1232
    • Raskin, P.1    Rendell, M.2    Riddle, M.C.3
  • 49
    • 36248935637 scopus 로고    scopus 로고
    • Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes
    • Yilmaz H, Gursoy A, Sahin M, et al. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol 2007;44:187-192
    • (2007) Acta Diabetol , vol.44 , pp. 187-192
    • Yilmaz, H.1    Gursoy, A.2    Sahin, M.3
  • 50
    • 4944262294 scopus 로고    scopus 로고
    • Combined thiazolidinedione-insulin therapy: Should we be concerned about safety?
    • Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004;27:841-856
    • (2004) Drug Saf , vol.27 , pp. 841-856
    • Scheen, A.J.1
  • 51
    • 75149137354 scopus 로고    scopus 로고
    • Actos (Pioglitazone). Takeda Pharmaceuticals America, Lincolnshire IL; Eli Lilly and Company Indianapolis, IN
    • Actos (Pioglitazone) Full Prescribing Information. Takeda Pharmaceuticals America, Lincolnshire, IL; Eli Lilly and Company, Indianapolis, IN, 1999
    • (1999) Full Prescribing Information
  • 52
    • 10744221639 scopus 로고    scopus 로고
    • Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association
    • Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263
    • (2004) Diabetes Care , vol.27 , pp. 256-263
    • Nesto, R.W.1    Bell, D.2    Bonow, R.O.3
  • 53
    • 75149179990 scopus 로고    scopus 로고
    • Available at: Accessed March 30, 2009
    • Pioglitazone and Rosiglitazone. Available at: www.drugstore.com. Accessed March 30, 2009
    • Pioglitazone and Rosiglitazone
  • 54
    • 0033304603 scopus 로고    scopus 로고
    • The glucagon-like peptides
    • Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20:876-913
    • (1999) Endocr Rev , vol.20 , pp. 876-913
    • Kieffer, T.J.1    Habener, J.F.2
  • 55
    • 7444228521 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    • Exenatide-113 Clinical Study Group
    • Buse JB, Henry RR, Han J, et al.; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-2635
    • (2004) Diabetes Care , vol.27 , pp. 2628-2635
    • Buse, J.B.1    Henry, R.R.2    Han, J.3
  • 56
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • Defronzo, R.A.1    Ratner, R.E.2    Han, J.3
  • 57
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28:1083-1091
    • (2005) Diabetes Care , vol.28 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 58
    • 33845472504 scopus 로고    scopus 로고
    • Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    • Sitagliptin Study 021 Group
    • Aschner P, Kipnes MS, Lunceford JK, et al.; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637
    • (2006) Diabetes Care , vol.29 , pp. 2632-2637
    • Aschner, P.1    Kipnes, M.S.2    Lunceford, J.K.3
  • 59
    • 33846817233 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized double- blind non-inferiority trial
    • Sitagliptin Study 024 Group
    • Nauck MA, Meininger G, Sheng D, et al.; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double- blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
    • (2007) Diabetes Obes Metab , vol.9 , pp. 194-205
    • Nauck, M.A.1    Meininger, G.2    Sheng, D.3
  • 60
    • 43449096512 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
    • Sitagliptin Study 801 Group
    • Scott R, Loeys T, Davies MJ, et al.; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-969
    • (2008) Diabetes Obes Metab , vol.10 , pp. 959-969
    • Scott, R.1    Loeys, T.2    Davies, M.J.3
  • 61
    • 75149151852 scopus 로고    scopus 로고
    • Byetta [Package Insert.] San Diego, CA, Amylin Pharmaceuticals, Inc., 2007
    • Byetta [Package Insert.] San Diego, CA, Amylin Pharmaceuticals, Inc., 2007
  • 62
    • 75149186924 scopus 로고    scopus 로고
    • Januvia [Package Insert.] Whitehouse Station, NJ, Merck & Co., Inc., 2006
    • Januvia [Package Insert.] Whitehouse Station, NJ, Merck & Co., Inc., 2006
  • 63
    • 48949098988 scopus 로고    scopus 로고
    • Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus
    • Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-292
    • (2008) Endocr Pract , vol.14 , pp. 285-292
    • Sheffield, C.A.1    Kane, M.P.2    Busch, R.S.3
  • 64
    • 75149182294 scopus 로고    scopus 로고
    • Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1c in obese type 2 diabetics on insulin
    • Presented at: June 9-13, 2006. Washington, DC
    • Bhatia R, Viswanathan P, Chaudhuri A, et al. Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1c in obese type 2 diabetics on insulin. Presented at Program and Abstracts of the American Diabetes Association 66th Scientific Sessions. June 9-13, 2006, Washington, DC, Abstract 422-P
    • Program and Abstracts of the American Diabetes Association 66th Scientific Sessions
    • Bhatia, R.1    Viswanathan, P.2    Chaudhuri, A.3
  • 65
    • 75149162384 scopus 로고    scopus 로고
    • Exenatide. Available at: Accessed March 30, 2009
    • Exenatide. Available at: www.drugstore.com. Accessed March 30, 2009
  • 66
    • 34247874561 scopus 로고    scopus 로고
    • Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    • Fonseca V, Schweizer D, Albrecht M, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-1155
    • (2007) Diabetologia , vol.50 , pp. 1148-1155
    • Fonseca, V.1    Schweizer, D.2    Albrecht, M.3
  • 67
    • 47049084841 scopus 로고    scopus 로고
    • Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
    • Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008; 40:427-430
    • (2008) Horm Metab Res , vol.40 , pp. 427-430
    • Fonseca, V.1    Baron, M.2    Shao, Q.3
  • 68
    • 84878644316 scopus 로고    scopus 로고
    • Available at: Accessed March 30, 2009
    • Sitagliptin. Available at: www.drugstore.com. Accessed March 30, 2009
    • Sitagliptin
  • 69
    • 75149192190 scopus 로고    scopus 로고
    • Acarbose [Package Insert.] Bonita Springs, FL, Cobalt Laboratories, Inc., 2006
    • Acarbose [Package Insert.] Bonita Springs, FL, Cobalt Laboratories, Inc., 2006
  • 71
    • 0029941276 scopus 로고    scopus 로고
    • An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM
    • Hara T, Nakamura J, Koh N, et al. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996;19:642-647
    • (1996) Diabetes Care , vol.19 , pp. 642-647
    • Hara, T.1    Nakamura, J.2    Koh, N.3
  • 72
    • 35048874614 scopus 로고    scopus 로고
    • Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy
    • Acarbose-Insulin Combination Study Group
    • Schnell O, Mertes G, Standl E; Acarbose-Insulin Combination Study Group. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 9:853-858
    • (2007) Diabetes Obes Metab , vol.9 , pp. 853-858
    • Schnell, O.1    Mertes, G.2    Standl, E.3
  • 73
    • 0033157223 scopus 로고    scopus 로고
    • Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late sulfonylurea failure
    • Standl E, Baumgarti H, Fuchtenbusch M, et al. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late sulfonylurea failure. Diabetes Obes Metab 2001;4:215-220
    • (2001) Diabetes Obes Metab , vol.4 , pp. 215-220
    • Standl, E.1    Baumgarti, H.2    Fuchtenbusch, M.3
  • 74
    • 0033139266 scopus 로고    scopus 로고
    • Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients
    • Guvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999;36:93-97
    • (1999) Acta Diabetol , vol.36 , pp. 93-97
    • Guvener, N.1    Gedik, O.2
  • 75
    • 36248935637 scopus 로고    scopus 로고
    • Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes
    • Hamiyet Y, Gursoy A, Sahin M, et al. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol 2007;44:187-192
    • (2007) Acta Diabetol , vol.44 , pp. 187-192
    • Hamiyet, Y.1    Gursoy, A.2    Sahin, M.3
  • 76
    • 0029032841 scopus 로고
    • A double-blind, placebocontrolled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes
    • Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind, placebocontrolled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995;18:928-932
    • (1995) Diabetes Care , vol.18 , pp. 928-932
    • Coniff, R.F.1    Shapiro, J.A.2    Seaton, T.B.3
  • 77
    • 0031767296 scopus 로고    scopus 로고
    • Efficacy and safety of acarbose in insulin- treated patients with type 2 diabetes
    • Kelley DE, Bidot P, Freedman Z, et al. Efficacy and safety of acarbose in insulin- treated patients with type 2 diabetes. Diabetes Care 1998;21: 2056-2061
    • (1998) Diabetes Care , vol.21 , pp. 2056-2061
    • Kelley, D.E.1    Bidot, P.2    Freedman, Z.3
  • 78
    • 75149135610 scopus 로고    scopus 로고
    • Acarbose. Available at: Accessed March 30, 2009
    • Acarbose. Available at: www.drugstore.com. Accessed March 30, 2009


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.